Developer docs
API playgroundTry for free, no card

Search company profiles

Redmile Group

Full company profile

uuid00002ln

Namestring
Redmile Group
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Redmile Group is a San Francisco-based healthcare investment firm founded in 2007 that deploys venture, growth, and crossover capital into biotechnology and life sciences companies. According to firmographics, it operates with 11-50 employees and reported $1.358 billion in reportable AUM as of a February 2026 SEC filing tied to its Nurix Therapeutics position. The firm invests across therapeutic areas including oncology, metabolic disease, genetic hearing loss, and inflammatory conditions, and across the full capital stack from Series B venture rounds to PIPEs, registered offerings, reserved capital increases, and direct open-market equity purchases.

The portfolio reflects a concentration in clinical-stage and commercially-staged biopharmaceutical platforms, with disclosed positions including Absci (AI-designed antibodies), Obsidian Therapeutics (tumor infiltrating lymphocyte cell therapy via reverse merger), Ambrosia Biosciences (oral small molecule GLP-1), Nurix Therapeutics (BTK degrader, 11.31% stake), Scholar Rock (latent myostatin inhibitor, 16.94% stake), Sensorion (gene therapy for hearing loss), ADC Therapeutics (ZYNLONTA), Bambusa Therapeutics (bispecific antibodies), and Augmedix (AI medical documentation). Redmile frequently participates alongside strategic pharma and tier-1 specialist investors such as Eli Lilly, Sanofi, TCGX, RA Capital, Blue Owl Healthcare Opportunities, and Deep Track Capital, and has co-led rounds including Ambrosia's $100 million Series B.

The firm's revenue model is conventional for a healthcare-focused private investment manager: management fees on AUM plus carried interest on portfolio realizations. There is no product, software, or technology platform of its own; pricing, distribution channels, and customer segmentation in the traditional sense do not apply. Limited partner composition, fund vintage, leadership compensation, and detailed ownership of the management company are not disclosed in available source material, and the firm has no public listing or parent company identified.

Short descriptiontext

Redmile Group is a San Francisco-based, healthcare-focused private investment firm founded in 2007 that deploys venture, growth, and crossover capital into clinical-stage and commercial biotechnology companies across multiple therapeutic areas.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
healthcare venture capital, biotech investment management, life sciences investing, crossover fund management, biotechnology equity investments
Industry1 code
PRIMARYBPADACAJ
Private Sector & Blended Finance Arms (IFC-type)
Business & Public Services/International Organizations & Development/International Financial Institutions & Development Banks
NAICS code1 code
  • Portfolio Management and Investment Advice523940
Product category
Healthcare Investment Management
Social media profiles1 record
Revenue model1 record
1Investment Returns and Fund Management
TypeOthers
Description

Redmile Group generates returns through equity investments in biotech and life sciences companies, participating in financing rounds such as Series B, PIPE offerings, registered offerings, and direct stock purchases. The firm holds significant stakes in portfolio companies (e.g., 11.31% of Nurix Therapeutics, 16.94% of Scholar Rock), and its $1.358 billion in reportable AUM suggests a fund management model where returns are realized through capital appreciation and exit events in its portfolio companies.

finance.yahoo.com
Cost components4 values
Personnel, Technology or R&D, Operations, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Redmile Group is a healthcare-focused investment firm that deploys venture, growth, and crossover capital into biotechnology and life sciences companies. The firm invests across multiple stages and instruments — including private financings (e.g., Series B) and public-market securities — targeting therapeutic developers, platform biotech, and healthcare technology businesses.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Portfolio company Absci raised $100 million in a stock offering with Redmile participation, with shares rising 22% post-announcement.
+4 more records
Product overview1 text field

Redmile Group is a venture capital and investment management firm specializing in the biotechnology and life sciences sector. The company invests in clinical-stage biopharmaceutical companies developing therapeutic programs across various disease areas including oncology, metabolic disorders, genetic hearing loss, and inflammatory conditions. As an investment firm, Redmile Group does not offer commercial products or technology platforms; its offering consists of capital investment and strategic support to portfolio companies.

Product and service2 records
1Healthcare venture and growth equity investments
CategoryVenture and growth capital
2Public-equity and PIPE investments in healthcare
CategoryPublic equity and PIPE investments
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Healthcare-focused crossover and venture investor that participates across private and public biotech financings. Directly comparable to Redmile in mandate, including co-investments in companies like Bambusa Therapeutics.

2Baker Bros. Advisors
TypeDirect peer
Description

Long-only healthcare and life sciences investment firm with deep biotech exposure across private rounds and public equities. Comparable to Redmile as a specialist healthcare investor building concentrated public/private positions.

TypeDirect peer
Description

Healthcare-dedicated investment platform spanning venture, growth, and public equities with multi-billion AUM. Directly comparable to Redmile in cross-stage healthcare deployment.

TypeDirect peer
Description

Healthcare-focused investment manager deploying capital across biotech equities and private financings. Similar crossover mandate and therapeutic breadth as Redmile.

TypeDirect peer
Description

Healthcare-focused hedge fund with public/private biotech crossover strategy. Directly comparable to Redmile in mandate and concentrated small/mid-cap biotech positioning.

TypeDirect peer
Description

Biotech-focused investment firm specializing in private and public healthcare equities. Highly comparable to Redmile in size, focus, and crossover deployment style.

TypeDirect peer
Description

Early-stage life sciences venture firm building biotech companies from inception through clinical development. Comparable to Redmile's biotech focus, though more weighted to earlier stages.

TypeDirect peer
Description

Leading healthcare and biotech venture firm investing across company formation through later stages. Comparable as a dedicated life sciences investor, though generally earlier-stage orientation.

TypeDirect peer
Description

Healthcare-focused investment franchise associated with Venrock, deploying across public and private biotech. Comparable to Redmile's crossover healthcare strategy.

TypeBroad incumbent
Description

Large, established healthcare investment firm with multi-strategy mandates spanning venture, public equities, royalties, and credit. Overlaps with Redmile in biotech equity investing but operates a broader platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment220 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Redmile Group

Healthcare Investment Managementredmilegroup.com

Redmile Group is a San Francisco-based, healthcare-focused private investment firm founded in 2007 that deploys venture, growth, and crossover capital into clinical-stage and commercial biotechnology companies across multiple therapeutic areas.

What Redmile Group does

Redmile Group is a San Francisco-based healthcare investment firm founded in 2007 that deploys venture, growth, and crossover capital into biotechnology and life sciences companies. According to firmographics, it operates with 11-50 employees and reported $1.358 billion in reportable AUM as of a February 2026 SEC filing tied to its Nurix Therapeutics position. The firm invests across therapeutic areas including oncology, metabolic disease, genetic hearing loss, and inflammatory conditions, and across the full capital stack from Series B venture rounds to PIPEs, registered offerings, reserved capital increases, and direct open-market equity purchases.

The portfolio reflects a concentration in clinical-stage and commercially-staged biopharmaceutical platforms, with disclosed positions including Absci (AI-designed antibodies), Obsidian Therapeutics (tumor infiltrating lymphocyte cell therapy via reverse merger), Ambrosia Biosciences (oral small molecule GLP-1), Nurix Therapeutics (BTK degrader, 11.31% stake), Scholar Rock (latent myostatin inhibitor, 16.94% stake), Sensorion (gene therapy for hearing loss), ADC Therapeutics (ZYNLONTA), Bambusa Therapeutics (bispecific antibodies), and Augmedix (AI medical documentation). Redmile frequently participates alongside strategic pharma and tier-1 specialist investors such as Eli Lilly, Sanofi, TCGX, RA Capital, Blue Owl Healthcare Opportunities, and Deep Track Capital, and has co-led rounds including Ambrosia's $100 million Series B.

The firm's revenue model is conventional for a healthcare-focused private investment manager: management fees on AUM plus carried interest on portfolio realizations. There is no product, software, or technology platform of its own; pricing, distribution channels, and customer segmentation in the traditional sense do not apply. Limited partner composition, fund vintage, leadership compensation, and detailed ownership of the management company are not disclosed in available source material, and the firm has no public listing or parent company identified.

Redmile Group firmographics

Firmographics
Name
Redmile Group
Website
https://redmilegroup.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
51–100 employees
Short description
Redmile Group is a San Francisco-based, healthcare-focused private investment firm founded in 2007 that deploys venture, growth, and crossover capital into clinical-stage and commercial biotechnology companies across multiple therapeutic areas.
Ownership category
akta.pro rank

Redmile Group industry classification

Industry
Product category
Healthcare Investment Management
NAICS
Portfolio Management and Investment Advice (523940)
akta.pro industry
PRIMARYBPADACAJ
Private Sector & Blended Finance Arms (IFC-type)
Business & Public Services/International Organizations & Development/International Financial Institutions & Development Banks

Keywords

  • Healthcare venture capital
  • Biotech investment management
  • Life sciences investing
  • Crossover fund management
  • Biotechnology equity investments

Where Redmile Group is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Markets served

Redmile Group business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Others

Revenue model

  1. Investment Returns and Fund Management: Redmile Group generates returns through equity investments in biotech and life sciences companies, participating in financing rounds such as Series B, PIPE offerings, registered offerings, and direct stock purchases. The firm holds significant stakes in portfolio companies (e.g., 11.31% of Nurix Therapeutics, 16.94% of Scholar Rock), and its $1.358 billion in reportable AUM suggests a fund management model where returns are realized through capital appreciation and exit events in its portfolio companies.

Redmile Group product offering

Product offering

Core offering

Redmile Group is a healthcare-focused investment firm that deploys venture, growth, and crossover capital into biotechnology and life sciences companies. The firm invests across multiple stages and instruments — including private financings (e.g., Series B) and public-market securities — targeting therapeutic developers, platform biotech, and healthcare technology businesses.

Product overview

Redmile Group is a venture capital and investment management firm specializing in the biotechnology and life sciences sector. The company invests in clinical-stage biopharmaceutical companies developing therapeutic programs across various disease areas including oncology, metabolic disorders, genetic hearing loss, and inflammatory conditions. As an investment firm, Redmile Group does not offer commercial products or technology platforms; its offering consists of capital investment and strategic support to portfolio companies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Healthcare venture and growth equity investments
  • Public-equity and PIPE investments in healthcare

Quantifiable outcome

  • Portfolio company Absci raised $100 million in a stock offering with Redmile participation, with shares rising 22% post-announcement.
  • +4 more outcomes

Companies that use Redmile Group

Customer profile

Ideal customer profiles1 record

Redmile Group technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Redmile Group partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Redmile Group competitors and assessment

Company assessment

Direct peers

  • RA Capital Management: Healthcare-focused crossover and venture investor that participates across private and public biotech financings. Directly comparable to Redmile in mandate, including co-investments in companies like Bambusa Therapeutics.
  • Baker Bros. Advisors: Long-only healthcare and life sciences investment firm with deep biotech exposure across private rounds and public equities. Comparable to Redmile as a specialist healthcare investor building concentrated public/private positions.
  • Orbimed Advisors: Healthcare-dedicated investment platform spanning venture, growth, and public equities with multi-billion AUM. Directly comparable to Redmile in cross-stage healthcare deployment.
  • Perceptive Advisors: Healthcare-focused investment manager deploying capital across biotech equities and private financings. Similar crossover mandate and therapeutic breadth as Redmile.
  • Cormorant Asset Management: Healthcare-focused hedge fund with public/private biotech crossover strategy. Directly comparable to Redmile in mandate and concentrated small/mid-cap biotech positioning.
  • EcoR1 Capital: Biotech-focused investment firm specializing in private and public healthcare equities. Highly comparable to Redmile in size, focus, and crossover deployment style.
  • Atlas Venture: Early-stage life sciences venture firm building biotech companies from inception through clinical development. Comparable to Redmile's biotech focus, though more weighted to earlier stages.
  • ARCH Venture Partners: Leading healthcare and biotech venture firm investing across company formation through later stages. Comparable as a dedicated life sciences investor, though generally earlier-stage orientation.
  • Venrock Healthcare Partners: Healthcare-focused investment franchise associated with Venrock, deploying across public and private biotech. Comparable to Redmile's crossover healthcare strategy.

Broad incumbents

  • Deerfield Management: Large, established healthcare investment firm with multi-strategy mandates spanning venture, public equities, royalties, and credit. Overlaps with Redmile in biotech equity investing but operates a broader platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Redmile Group social profiles

Digital presence

Redmile Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Redmile Group leadership team

Management profile

Number of profiles

Profiles5 records

Redmile Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Redmile Group M&A and investment

M&A and investment

M&A

Investments220 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Redmile Group

What does Redmile Group do?

Redmile Group is a healthcare-focused investment firm that deploys venture, growth, and crossover capital into biotechnology and life sciences companies. The firm invests across multiple stages and instruments — including private financings (e.g., Series B) and public-market securities — targeting therapeutic developers, platform biotech, and healthcare technology businesses.

Is Redmile Group a public or private company?

Redmile Group is a private company. It is classified as unknown and is currently operating.

When was Redmile Group founded?

Redmile Group was founded in 2007. It employs 51 to 100 people.

Where is Redmile Group based?

Redmile Group is headquartered in San Francisco, United States, in the North America region.

How does Redmile Group make money?

One revenue line is on record: investment Returns and Fund Management.

Who are Redmile Group's main competitors?

Direct peers on record are RA Capital Management, Baker Bros. Advisors, Orbimed Advisors, Perceptive Advisors, Cormorant Asset Management, EcoR1 Capital, Atlas Venture, ARCH Venture Partners and Venrock Healthcare Partners. Deerfield Management is listed as a broad incumbent.

Does Redmile Group have an API?

No public API is recorded for Redmile Group.

What industry is Redmile Group in?

Redmile Group's product category is Healthcare Investment Management. Its primary akta.pro industry code is BPADACAJ, Private Sector & Blended Finance Arms (IFC-type). Its NAICS code is 523940.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BiontechBioNTech Secures USD 270 Million in Series A FinancingBioNTech completed a $270 million Series A financing round led by Redmile Group, with participation from Janus Henderson, Invus, Fidelity, and others. The company will use the funds to advance its clinical pipeline of individualized immunotherapies, including mRNA and CAR-T therapies for cancer.European BiotechnologyRedx raises $36M to fund Phase 2 Crohn’s disease trialRedx raised $36M in a Series A round, led by Abingworth, to fund its Phase 2 trial of gut-restricted ROCK inhibitor RXC008 for fibrostenotic Crohn's disease. The financing includes a $68M private placement, extending the combined company's cash runway to 2029. Redx aims to report Phase 2 topline data in the second half of 2028.BusinessCloud$125m financing to see Macclesfield’s Redx list on NasdaqRedx Pharma, a Macclesfield-based biotech, agreed a $125m financing deal to list on Nasdaq as Fibrx Therapeutics. The deal includes a $36m Series A led by Abingworth and a $68m private placement, with Sky Bioscience acquiring Redx. The combined company will fund operations through 2029 and key clinical milestones, including RXC008 Phase 2 data expected in H2 2028.Quiver Quantitative$ADCT stock is down 17% today. Here's what we see in our data. | ADCT Stock NewsADCT stock declined 17% in intraday trading with approximately $1 million in volume. Recent data shows significant insider selling by Redmile Group and notable portfolio adjustments by major institutional investors such as OrbiMed Advisors, Millennium Management, and BlackRock. Analyst price targets for the company remain widely dispersed, ranging from $2.0 to $8.0.Defense WorldAttovia Therapeutics (NASDAQ:ATTO) Major Shareholder Redmile Group, Llc Purchases 200,000 SharesRedmile Group, Llc purchased 200,000 shares of Attovia Therapeutics stock at an average price of $17.00 per share, increasing its position by 25.55% to a total holding of 982,854 shares. This transaction was disclosed in an SEC filing on August 6th, coinciding with other institutional activity such as BlackRock Inc. raising its stake by 23.4% during the second quarter.FinSMEsBios Life Raises $25M in Seed FundingBios Life, a Boston-based AI cancer surveillance platform, raised $25M in seed funding led by Redmile, Vsquared Ventures, and Kindred Capital. The company will use the funds to build its personalized cancer screening and survivorship care platform and expand across the United States.Venture Capital Access OnlineBios Life Emerges from Stealth with $25M and Partners with Tempus to Personalize Cancer Screening and SurveillanceBios Life emerged from stealth with $25M in seed financing led by Redmile, Vsquared Ventures, and Kindred Capital. The company will partner with Tempus to train predictive models for cancer surveillance, targeting high-risk individuals and survivors. The platform launches in the US in the second half of 2026.pharmaphorumEx-BioNTech execs launch 'AI-native' cancer companyEx-BioNTech executives Ryan Richardson and Zach Taylor launched Bios Life, an AI-native cancer surveillance company, with $25 million in seed financing led by Redmile, Vsquared Ventures, and Kindred Capital. The company will partner with AI specialist Tempus to build a virtual clinic for personalized cancer screening and survivorship care, planning to launch before year-end.EIN PresswireBios Life Emerges from Stealth with $25M and Partners with Tempus to Personalize Cancer Screening and SurveillanceBios Life emerged from stealth with $25 million in seed financing led by Redmile, Vsquared Ventures, and Kindred Capital. The company announced a multi-year alliance with Tempus to train and validate its predictive cancer surveillance models. Its platform launches in the US in the second half of 2026.Quiver QuantitativeInsider Stock Purchases: August 08, 2026 | ATTO Stock NewsOn August 8, 2026, Quiver Quantitative reported significant open market insider purchases for ATTOVIA THERAPEUTICS, INC., including a $6.8 million buy by Redmile Group, LLC. The report also highlighted Navios Maritime Partners L.P., noting that insider Angeliki Frangou has executed 95 purchases over the past six months.